Campbell DJ. Control of regulatory T cell migration, function, and homeostasis[J]. J Immunol, 2015, 195(6): 2507⁃2513. DOI: 10.4049/jimmunol.1500801.
[2]
Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus[J]. Eur J Immunol, 2015, 45(2): 344⁃355. DOI: 10.1002/eji.201344280.
[3]
Spence A, Klementowicz JE, Bluestone JA, et al. Targeting Treg signaling for the treatment of autoimmune diseases[J]. Curr Opin Immunol, 2015, 37: 11⁃20. DOI: 10.1016/j.coi.2015.09.002.
[4]
Yang J, Chu Y, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus[J]. Arthritis Rheum, 2009, 60(5): 1472⁃1483. DOI: 10.1002/art.24499.
[5]
Venigalla RK, Tretter T, Krienke S, et al. Reduced CD4+, CD25⁃ T cell sensitivity to the suppressive function of CD4+, CD25high, CD127 ⁃/low regulatory T cells in patients with active systemic lupus erythematosus[J]. Arthritis Rheum, 2008, 58(7): 2120⁃2130. DOI: 10.1002/art.23556.
[6]
Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythe⁃matosus[J]. Eur J Immunol, 2015, 45(2): 344⁃355. DOI: 10.1002/eji.201344280.
[7]
Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxy⁃chloroquine in human disease[J]. Semin Arthritis Rheum, 2013, 43(2): 264⁃272. DOI: 10.1016/j.semarthrit.2013.01.001.
[8]
Costedoat⁃Chalumeau N, Dunogué B, Morel N, et al. Hydroxy⁃chloroquine: a multifaceted treatment in lupus[J]. Presse Med, 2014, 43(6 Pt 2): e167⁃180. DOI: 10.1016/j.lpm.2014.03.007.